Loading
Bacteria-based Immunotherapy / Tumor Microenvironment / Immunotherapy · Journal article
Cancer Biology & Therapy · June 4, 2026
A consensus or society position rather than new primary data.
This is a narrative review article that synthesizes recent advances in engineering bacteria as vectors for cancer immunotherapy using synthetic biology approaches. It describes mechanistic pathways (innate and adaptive immune activation via PAMPs), engineering strategies (hypoxia-responsive promoters, bacterial swarming, extracellular vesicles), and synergistic combinations with other modalities, but reports no original experimental data or clinical trial results.
Narrative review.
Bacterial anticancer strategies have progressed from direct administration (Coley's toxins, BCG) to engineered strains such as Salmonella VNP20009 and Clostridium novyi-NT using synthetic biology Engineered bacterial systems can produce antineoplastic agents in situ, act as biosensors, and serve as targeted delivery platforms Key bacterial PAMPs (lipopolysaccharide, flagellin) are recognized by specific pattern-recognition receptors (TLR4, TLR5) to trigger innate immune activation
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a narrative review synthesizing existing knowledge on synthetic biology approaches to bacterial cancer immunotherapy, without reporting original experimental data, primary endpoints, or comparative efficacy claims.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
In recent years, synthetic biology has been widely applied to engineer and program cellular behaviors. Using this approach, bacteria can be designed to express immunotherapeutic agents, improve tumor targeting, and deliver therapeutic payloads directly to tumor sites. To further improve efficacy, strategies such as hypoxia-responsive promoters, bacterial swarming, and extracellular vesicles (EVs) have been investigated, along with the synergistic effects of combining bacterial therapy with other treatments (e.g., photodynamic therapy, chemotherapy, immune checkpoint inhibitors). This review summarizes recent advances in synthetic biology for bacteria-based cancer immunotherapies, focusing on how bacterial agents activate the immune system and the engineering strategies used to achieve tumor targeting.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.